

2025 OAOS

## ANNUALORTHOPAEDIC CONFERENCE

HYATT REGENCY PORTLAND
SEPTEMBER 26-27, 2025

### I have no relevant financial relationships with ineligible companies to disclose.



#### Obesity Medicine for Orthopedic Practice

Moving High Risk Patients Safely to the Table



#### Leslie Sanchez-Goettler, MD, MAR, MPhil

Board Certified in Internal Medicine

88 88 88 88

Diplomate of the ABOM


Past medical history of heart stuff and blah, blah, blah. Plan OR tonight.

--An orthopedic surgeon's H&P








## SURWEY













If you die whilst waiting to hit your BMI target for your surgery, please cancel your appointment

## Collaborate to Operate







## Let Me Take That Off Your Plate



Clinical Case



### 58 yc


- BMI 52
- Severe Left Knee
  Osteoarthritis



#### PMH:

- HTN
- HLD
- OSA





#### FAILED ...









## Candidate for TKA



• • • • • •



EXCEPT-

Surgery deferred due to BMI = 52






# 

## Five Rationales for BM Cutoffs

#### **High BMI**





### Infection Risk


2-3X higher risk of periprosthetic joint infection



## Wound Healing & Complications

Delayed wound healing

 †Risk of hematoma/seroma








## Anesthetic & Operative Challenges

†Risk of airway difficulty and Cardiopulm complications

## (d) Functional Outcomes

Worse implant survival and functional recovery









## Readmission & Cost

Higher 90-day readmission and revision rates




"No, that doesn't make any difference either, Miss Jones."



#### Lost 135 LBS.




#### Lost 170 LBS.






#### Lost 140 LBS.








# Goal Timeline? 1-2 lbs/week



## Prehab & Whole-Person Approach







#### SPHERES Framework

#### "SPHERES" Overview

Strength Training



Hormone Replacement Therapy

The Emotional Wellness

Red Light Therapy

Effective Weight Loss Medication

zz Sleep





## Strength Training

Preserves and builds lean muscle mass

Improves balance and joint stability

Accelerates rehab and recovery



#### 3D Body Scanning Optical Imaging



3D Body Scanning Optical Imaging, 98% correlated with bone density, Near Perfect repeatability





#### Proper Nutrition


- 1. Prioritize Protein
- 2.Increase Fiber
- 3. Reduce Added Sugar
- 4. Reduce Alcohol
- 5.Healthy Fats





# Longterm Orthopedic success starts in the Kitchen - not the OR











## Proper Nutrition Reduce Added Sugar

· Lowers inflammation

· Improves glucose control

· Supports fat loss



#### Proper Nutrition


Reduce Alcohol


· Improves wound healing

· Reduces Anesthesia Risk

Supports liver and metabolic health


















#### Hormone Replacement Therapy





#### Hormone Replacement Therapy

Maintains muscle and bone strength



#### Hormone Replacement Therapy

Improves metabolic and cardiovascular health



#### Hormone Replacement Therapy

Enhances sleep, mood, and energy











# Red Light Therapy

- Reduces Inflammation
- Promotes tissue repair



# Effective Weight Loss 2mg/0.75 ml Medications

- · Appetite suppression 5 ml
- · Craving control
- Enhanced energy expenditure tirzepatide 5 mg


# Sleep/OSA

Supports immune function

· Regulates blood sugar

# Sleep/OSA

OSA management reduces complications



#### "SPHERES" Overview

Strength Training



Hormone Replacement Therapy

The Emotional Wellness

Red Light Therapy

Effective Weight Loss Medication

zz Sleep








# Indication Weight Loss Medications

• Initial BMI > 30

BMI > 27 and
 ≥ 1 weight-related comorbidity

NAME OF TAXABLE PARTY.

#### Effective Weight Loss Medications



NAME OF THE PERSON OF THE PERS

Mechanism DRUG **Key Effects Appetite** Norepinephrine Phentermine Satiety GABA Modulation Topiramate Taste Alteration Cravings



DRUG

Mechanism

**Key Effects** 

Bupropion

+

Naltrexone

Dopamine/NE reuptake inhibition

Opioid receptor blockade

Hunger

Reward-driven

\$\\$\\$\\$ eating



DRUG

Mechanism

**Key Effects** 

Semaglutide
(GLP1
Agonist)

Slows gastric emptying

Appetite

T Satiety

Intake

Improves insulin sensitivity

† Glucose Regulation



DRUG

Mechanism

**Key Effects** 

Tirzepatide
(Dual GIP
and
GLP1
agonist)

Slows gastric emptying

† Satiety

1 Insulin sensitivity

Strong appetite suppression

Better glycemic control



### Effective Weight Loss Medications

Surmountl Trial (NEJM 2022)

#### Study Design:

- Randomized
- Double-blind
- Placebo-controlled



# Effective Weight Loss Medications Surmountl Trial (NEJM 2022)

- Tirzepatide
- Once weekly
- Adults with obesity or overweight

without diabetes



### Tirzepatide Surmountl Trial

72 weeks

15 mg: 20.9%

Placebo: 3.1%

NAME OF THE PERSON OF THE PERS

# Effective Wgt Loss Meds - Comparison Surpass-2 Trial (NEJM 2021)

- Tirzepatide (5, 10, 15 mg) vs.
- Semaglutide (1 mg)
- Adults with type 2DM



### Effective Wgt Loss Meds - Comparison

Surpass-2 Trial

• Results:

Tirzepatide > weight loss and

better HbAlc reduction than

Semaglutide 1 mg



### Effective Wgt Loss Meds - Comparison

Surpass-2 Trial

- · Unclear Comparisons:
  - o No data comparing tirzepatide vs

semaglutide 2.4 mg (therapeutic)



### Effective Wgt Loss Meds - Comparison

Surpass-2 Trial

- · Unclear Comparisons:
  - Relative effectiveness for weight

loss remains uncertain



### Weight Loss Medication Benefits Beyond Weight Loss

- Improve Glycemic Control
- Lowers Blood Pressure
- Reduces CV Risk



# Weight Loss Medication Benefits Beyond Weight Loss


- Decreased Inflammation
- Improved Sleep Quality
- Better Liver Health



# Weight Loss Medication Benefits Beyond Weight Loss

- Enhanced Joint Health
- Improved Mental Health
- Increased Longevity

NAME OF THE PERSON OF THE PERS



### Perioperative Risks of Malnutrition

- Poor wound healing
- Infection
- Impaired recovery
- Longer hospital stays

# Comparative Perspective

Malnutrition higher direct risk of morbidity and mortality than obesity

### Comparative Perspective

Cause: Protein and micronutrient deficiency

# Sarcopenic Obesity

- Combination 2 disease states:
   Low muscle mass + high fat
   mass
- Highest operative risk

# Sarcopenic Obesity

- Lack lean muscle for recovery
- More Inflammation
- Poor functional capacity


# Sarcopenic Obesity

- Infection
- Delayed wound healing
- Mortality

#### Prehab Goal

- · Decrease body fat
- · Increase lean body mass





# Questions Screening Tool









2. Has the patient lost >5% body weight in 3-6 months, or noticed fatigue or muscle loss?



Questions Screening Tool for Orthopedics

3. Limited mobility and struggling to meet preoperative thresholds?






# YES

# Tefer to Obesity Medicine

#### What to Look For in Obesity Medicine Doctor

- 1. ABOM Certified
- 2. Holistic Approach
- 3. Communication





You'll have one less thing to manage



You'll see better surgical outcomes



You will have shorter delays to surgery



Your patients heal stronger and return to function sooner

### Down 180 LBS.





#### Follow us for more inspiration:





- www.instagram.com/radiancemd\_org
- www.linkedin.com/company/radiancemd
- www.tiktok.com/@transform\_radiancemd
- www.radiancemd.org



SCAN ME

971-IDANCE2

# Wisdom from an Obesity Medicine Doctor

# Nothing tastes as good as fat loss feels...



#### ORTHOPEDICS AND OBESITY MEDICINE

#### RESOURCE LIST

- 1. Ramanathan R, Lee JY, Dalton JF, Lin RT, Lee I, Gonzalez C Jr, Shaw JD, Schroeder GD, Kepler CK, Spitnale M, Vaccaro AR, Gabrielli AS, Wawrose RA. GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative and Outcomes: An Orthopaedic Surgeon's Perspective. J Bone Joint Surg Am. 2025 Jul 10. doi: 10.2106/JBJS.24.01287. Epub ahead of print. PMID: 40638702.
- 2. Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmun Rev. 2025 Jul 3;24(9):103864. doi: 10.1016/j.autrev.2025.103864. Epub ahead of print. PMID: 40617296.
- 3. Chan YC, Chuang SH, Kuo YJ, Lian YZ, Chen YP. The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2025 Jul 3:S0883 5403(25)00834-4. doi: 10.1016/j.arth.2025.06.083. Epub ahead of print. PMID: 40617546.
- 4. Berenbaum F. Beyond weight loss: GLP-1 emerges as a disease-modifying signal in osteoarthritis. Osteoarthritis Cartilage. 2025 Jun 20:S1063-4584(25)01062-3. doi: 10.1016/j.joca.2025.06.011. Epub ahead of print. PMID: 40544946.
- 5. Heo KY, Goel RK, Woltemath A, Fuqua A, Hrudka BT, Syed O, Arellano E, Premkumar A, Wilson JM. Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes. J Arthroplasty. 2025 Jun;40(6):1413-1418.e1. doi: 10.1016/j.arth.2024.10.099. Epub 2024 Oct 30. PMID: 39486470.
- 6. Barkyoumb D, Muhammad F, Smith ZA, Shakir HJ. Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes. J Spine Surg. 2025 Jun 27;11(2):339-346. doi: 10.21037/jss-24-152. Epub 2025 Apr 14. PMID: 40621386; PMCID: PMC12226182.

#### ORTHOPEDICS AND OBESITY MEDICINE

#### RESOURCE LIST

- 7. Al-Najim W, Raposo A, BinMowyna MN, le Roux CW. Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. Nutrients. 2025 Jun 5;17(11):1934. doi: 10.3390/nu17111934. PMID: 40507203; PMCID: PMC12157928.
- 8. Gatto A, Liu K, Milan N, Wong S. The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Curr Rev Musculoskelet Med. 2025 May 15. doi: 10.1007/s12178-025-09978-3. Epub ahead of print. PMID: 40372699
- 9. Ryan DH. New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Rev Endocr Metab Disord. 2025 May 5. doi: 10.1007/s11154-025-09967-4. Epub ahead of print. PMID: 40320499.
- 10. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Fatima Cody S, Callahan EA. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Lifestyle Med. 2025 May 30:15598276251344827. doi: 10.1177/15598276251344827. Epub ahead of print. PMID: 40452753; PMCID: PMC12125019.
- 11. Ryan M, Megyeri S, Nuffer W, Trujillo JM. The potential role of GLP-1 receptor agonists in osteoarthritis. Pharmacotherapy. 2025 Mar;45(3):177-186. doi: 10.1002/phar.70005. Epub 2025 Feb 20. PMID: 39980227.
- 12. Kim BI, LaValva SM, Parks ML, Sculco PK, Della Valle AG, Lee GC. Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA. J Bone Joint Surg Am. 2025 Feb 19;107(4):348-355. doi: 10.2106/JBJS.24.00468. Epub 2024 Dec 24. PMID: 39719003.

#### ORTHOPEDICS AND OBESITY MEDICINE

#### RESOURCE LIST

- 13. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, Ghanem OM, Levy S, Joshi GP, LaMasters T; Representing the American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, American Society of Anesthesiologists, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025 Jan;39(1):180-183. doi: 10.1007/s00464-024-11263-2. Epub 2024 Oct 29. PMID: 39370500; PMCID: PMC11666732.
- 14. Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE; STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664. PMID: 39476339.
- 15. Chang MG, Bittner EA. Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations. Can J Anaesth. 2024 Sep;71(9):1302-1315. doi: 10.1007/s12630 024-02810-5. Epub 2024 Aug 26. PMID: 39187641.
- 16. Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, Li Z, Richards J, Butsch WS, Jouravskaya I, Vanderman KS, Neff LM. Nutritional considerations with antiobesity medications. Obesity (Silver Spring). 2024 Sep;32(9):1613-1631. doi: 10.1002/oby.24067. Epub 2024 Jun 10. PMID: 38853526.
- 17. Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, Green DJ. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024 Oct 1;47(10):1718-1730. doi: 10.2337/dci23-0100. PMID: 38687506.